Ann: Successful Completion of Dosing in First Patient Cohort, page-21

The updated presentation from Thursday for anyone who missed it. Notable points that stood out to me, many of them new:

A) Phase 1 basket trial is in the works targeting other neuroectodermal tumours that show can bind to CLTX
--> Colorectal cancer, melanoma, small cell lung cancer, prostate cancer, ewing's sarcoma
--> increasing addressable market working on existing preclinical data that shows CLTX is just as effective in these as well as glioblastoma


B) ~19mins: possibility for a multi-pronged CAR-T platform with CLTX and other novel targets on the 1 treatment-
--> "...looking at other CAR designs on top of CLTX" " Looking at 2 tumour targeting domains"
--> expanding from traditional CAR-T single-pronged receptor targets to multiple
--> this would facilitate a product pipeline that could extend the original patents with variations in targets (WITH CLTX)

C) ~19mins"looking at allogeneic cell sources long term"
--> can use off the shelf, readily available synthetic/donor cells to treat patients instead of using own T-cells
--> traditional CAR-T being costly and time inefficient with extraction --> manufacturing process/site --> back to patient
- Of note, it's priced accordingly and precedence has been set at costs of $100k+ for CAR-T therapy
- Forward thinking here may keep CHM's product competitive for longer

D) ~24mins Road to commercialisation

- "Phase 1 trial finished ~September 2022"
--> Jennifer's comment on commercialisation standard for CAR-T therapies from phase 1 trial --> commercialisation is around 4 years
- keeping in mind it usually takes on average 10years, and $2.6billion to get a product from pre-clinical to commercialisation in drugs required to undergo full phase 3 studies - a requirement CAR-T's have not had to meet historically --> we are not being valued accordingly imo See reference here
- at 28.30, question answered: --> recruitment speed will now dramatically increase since FDA mandated dosing phase has ended (4 patients dosed in 6 months, we can see this rate increase dramatically to meet the required 18-36 patients)

E) ~27mins risks of treatment discussed from question- "safety profile here may mean that safety profile is superior to existing cytological CAR's"
--> not used systemically via vein like others; See below - injected locally --> less risk of cytokine storm etc hypothesised by Jennifer Chow

One thing that has really been drummed home in this presentation is the fact that CHM isn't only about treating glioblastoma with CLTX-armed CAR-T therapy. They're looking at other neuroectodermal cancers that have also showed good pre-clinical data. They're looking at the possibility of Allogeinic 'off the shelf' products commercially down the line. They're looking at possible multi-receptor pronged CAR-T therapy which would not only increase it's sensitivity, but possibly lead to fresh restarts on patents to further than 2036 on each of these products. Lastly and possibly most significantly to me, they're looking at other novel CAR designs on top of CLTX.

We might have an (albeit conservative) timeline for a phase 1 trial, but we have no idea if products will be acquired, nor if/when other cancer phase 1 trials will commence. This company isn't just a simple CAR-T therapy company, and it hasn't hired a management team who would be satisfied with a project as such. This is a company looking to optimise the safety of CAR-T therapy with novel administration, a company looking at making CAR-T therapy allogeinic, and a company looking to broaden its horizons with other products and cancer targets. We're cashed up with $39.3million AUD, anything is possible.

Encouraging first update and nice to have an investor presentation I've no doubt will be chewed over the weekend. We know the appetite is there for this to go to $0.4 on hype alone, so those who've flipped will undoubtedly want back in.